Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

NCT ID: NCT03497273

Last Updated: 2020-03-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-20
• Study Completion Date: 2020-02-17

Brief Summary

The purpose of this study is to assess the safety and tolerability of itacitinib in combination with corticosteroids in Japanese subjects with Grades II to IV acute graft-versus-host disease (aGVHD).

Conditions

Acute Graft-versus-host Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Itacitinib + corticosteroids

Itacitinib administered in combination with corticosteroids.

Group Type: EXPERIMENTAL

Itacitinib

Intervention Type: DRUG

Itacitinib administered orally once daily at the protocol-defined dose.

Corticosteroid

Intervention Type: DRUG

Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.

Interventions

Itacitinib

Itacitinib administered orally once daily at the protocol-defined dose.

Intervention Type: DRUG

Corticosteroid

Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.

Intervention Type: DRUG

Other Intervention Names

INCB039110

Eligibility Criteria

Inclusion Criteria

• Japanese; subject was born in Japan and has not lived outside of Japan for a total of > 10 years, and subject can trace maternal and paternal Japanese ancestry.
• Has undergone 1 allo-hematopoietic stem cell transplant (HSCT) from any donor and source (unrelated, sibling, haploidentical donors with any matching) using bone marrow, peripheral blood or cord blood for hematologic malignancies. Recipients of myeloablative and reduced-intensity conditioning regimens are eligible.
• Clinically suspected Grades II to IV aGVHD as per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria, occurring after allo-HSCT and any anti-GVHD prophylactic medication.
• Evidence of myeloid engraftment (eg, absolute neutrophil count [ANC] ≥ 0.5 × 10^9/L for 3 consecutive assessments if ablative therapy was previously used). Use of growth factor supplementation is allowed.
• Female subjects should agree to use medically acceptable contraceptive measures, should not be breastfeeding, and must have a negative pregnancy test before the start of study drug administration if of childbearing potential or must have evidence of non-childbearing potential by fulfilling protocol-defined criteria at screening.

Exclusion Criteria

• Has received more than 1 allo-HSCT.
• Has received more than 2 days of systemic corticosteroids for aGVHD.
• Presence of GVHD overlap syndrome.
• Presence of an active uncontrolled infection (defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection; persisting fever without signs or symptoms will not be interpreted as an active uncontrolled infection).
• Known human immunodeficiency virus infection.
• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation. For subjects with negative HBsAg and positive total hepatitis B core antibody and for subjects who are positive for HCV antibody, HBV DNA and HCV RNA must be undetectable upon testing.
• Evidence of relapsed primary disease or having been treated for relapse after the allo-HSCT was performed.
• Any corticosteroid therapy (for indication other than GVHD) at doses > 1 mg/kg per day methylprednisolone or equivalent within 7 days of enrollment.
• Severe organ dysfunction unrelated to underlying GVHD, including the following:

• Cholestatic disorders or unresolved veno-occlusive disease of the liver.
• Clinically significant or uncontrolled cardiac disease.
• Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
• Serum creatinine > 2.0 mg/dL or creatinine clearance < 40 mL/min measured or calculated by Cockroft-Gault equation
• Received Janus kinase (JAK) inhibitor therapy after allo-HSCT for any indication. Treatment with a JAK inhibitor before allo-HSCT is permitted.
• Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Incyte Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rodica Morariu-Zamfir, MD

Role: STUDY_DIRECTOR

Incyte Corporation

Locations

JA-Aichi Anjo Kosei Hospital

Anjo-Shi, Aichi-ken, Japan

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

Hokuyukai Sapporo Hokuyu Hospital

Sapporo, Hokkaido, Japan

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

Hyogo College of Medicine Hospital

Nishinomiya-Shi, Hyōgo, Japan

University of Tsukuba Hospital

Tsukuba, Ibaraki, Japan

Jiaikai Imamura General Hospital

Kagoshima, Kagoshima-ken, Japan

Tokai University Hospital

Isehara-Shi, Kanagawa, Japan

Kanagawa Cancer Center

Yokohama, Kanagawa, Japan

NHO Kumamoto Medical Center

Kumamoto, Kumamoto, Japan

Tohoku University Hospital

Sendai, Miyagi, Japan

Okayama University Hospital

Okayama, Okayama-ken, Japan

Osaka City University Hospital

Osaka, Osaka, Japan

Shizuoka Cancer Center

Nagaizumi-cho, Shizuoka, Japan

Jichi Medical University Hospital

Shimotsuke-shi, Tochigi, Japan

St. Luke's International Hospital

Chūōku, Tokyo-To, Japan

Jikei University Hospital

Minatoku, Tokyo-To, Japan

Countries

Japan

Other Identifiers

INCB 39110-118

Identifier Type: -

Identifier Source: org_study_id